Perfil da calprotectina fecal no acompanhamento dos pacientes portadores de doença inflamatória intestinal assistidos pelo CEMEC

Abstract

Inflammatory bowel diseases (IBD) encompasses Chron's Disease (CD) and ulcerative colitis (UC), which are chronical clinical conditions, with periods of remission and activity, being potentially serious, with risk of irreversible complications. Thus, patients need a quick approach and effective clinical follow-up, through easily accessible complementary tests, such as fecal calprotectin (FC). To know the FC profile of patients with IBD assisted by the intestinal pathologies outpatient clinic of CEMEC. A descriptive, observational, crosssectional and retrospective study was carried out based on the analysis of data recorded in the patients' medical records, with the results of FC and colonoscopy, followed up from August 2021 to May 2022. 16 patients with IBD were accompanied by the clinic, with UC being diagnosed in 68.75% and CD in 31.25%, with a predominance of females (75%). The FC ranged between 9 and 6,000 mcg/g, with a median equal to 193.0 mcg/g (95% CI 44.0 – 1,497); 25% (4/16; 95%CI 10.2 – 49.5) of the patients had a FC below 50 mcg/g, 25.0% (4/16, 95%CI 10.2 – 49.5) between 50 and 200 mcg/g and 50.0% (8/16, 95%CI 28.0 - 72.0) above 200 mcg/g. It was observed that the patients with the most severe symptoms and clinical manifestations had the tendency to present higher FC results. FC is na accessible and reliable disease marker in the monitoring of disease activity and remission, promoting important benefits in the treatment and control of IBD.